en
Scientific article
French

Inhibiteurs sélectifs de la recapture de la sérotonine (ISRS) et ostéoporose

Published inRevue médicale suisse, vol. 7, no. 299, p. 1299-1304
Publication date2011
Abstract

Selective serotonin reuptake inhibitors (SSRI) represent the first-line treatment of depression. Several studies demonstrate that use of therapeutical doses of SSRI is associated with a decreased bone mineral density (BMD) and an increased risk of fracture. Mechanisms of action of SSRI on bone tissue are not totally clarified. These treatments would be associated with an increased risk of falls and would also have a direct effect on bone metabolism. Regarding proofs existing of the implication of SSRI on osteoporosis, while waiting for larger-scale prospective studies, it appears reasonable that practitioners assess bone loss within risk groups of patients treated with SSRI.

Keywords
  • Bone Density/drug effects
  • Depression/drug therapy
  • Evidence-Based Medicine
  • Humans
  • Osteoporosis/chemically induced/prevention & control
  • Risk Factors
  • Serotonin Uptake Inhibitors/administration & dosage/adverse effects
Research group
Citation (ISO format)
FÉTIQUE-WILL, Anne-Catherine, CHEVALLEY, Thierry, RIZZOLI, René. Inhibiteurs sélectifs de la recapture de la sérotonine (ISRS) et ostéoporose. In: Revue médicale suisse, 2011, vol. 7, n° 299, p. 1299–1304.
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1660-9379
618views
1downloads

Technical informations

Creation12/20/2013 9:52:00 AM
First validation12/20/2013 9:52:00 AM
Update time03/14/2023 8:47:02 PM
Status update03/14/2023 8:47:02 PM
Last indexation01/16/2024 8:42:09 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack